Gyre Therapeutics, Inc. GYRE Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Gyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.
The official record: Gyre Therapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Gyre Therapeutics, Inc.'s additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Gyre Therapeutics, Inc.'s additional paid-in capital?
- Gyre Therapeutics, Inc. (GYRE) reported additional paid-in capital of $174.65M in Q1 2026.
- How has Gyre Therapeutics, Inc.'s additional paid-in capital changed year-over-year?
- Gyre Therapeutics, Inc.'s additional paid-in capital increased by 26.4% year-over-year, from $138.18M to $174.65M.
- What is the long-term trend for Gyre Therapeutics, Inc.'s additional paid-in capital?
- Over 5 years (2020 to 2025), Gyre Therapeutics, Inc.'s additional paid-in capital has grown at a -15.1% compound annual growth rate (CAGR), from $390.8M to $172.05M.
- What does additional paid-in capital mean?
- Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.